Cord Blood News 12.05 February 13, 2020 | |
| |
TOP STORYUse of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors In this Phase I and II trial, scientists administered HLA-mismatched anti-CD19 chimeric antigen receptor (CAR)-natural killer cells derived from cord blood to 11 patients with relapsed or refractory CD19-positive cancers. [N Engl J Med] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Safety and efficacy of ATIR101 administered after T-cell-depleted haploidentical (TCD-haplo) hematopoietic stem-cell transplantation (HSCT) without post-transplant immunosuppressors were evaluated in a Phase II, multicenter study of 23 patients with acute leukemia and compared with an observational cohort undergoing TCD-haplo alone, matched unrelated donor, mismatched unrelated donor, and umbilical cord blood HSCT. [Leukemia] Full Article Investigators found that Wharton’s jelly (WJ)‐MSCs protected mice from lethal dose of ionizing radiation even when transplanted up to 24 hours after‐irradiation and combination of WJ‐MSCs and antibiotic could further expand the window of protection offered by WJ‐MSCs. [Am J Transplant] Abstract The adipogenic differentiation capacity of MSCs was shown to influence ciliogenesis. MSCs transfected with intraflagellar transport 88 small interfering RNA, which blocked the assembly and maintenance of cilia, were examined to confirm the relationship between adipogenesis and ciliogenesis. [J Tissue Eng Regen Med] Abstract Using nationwide registration data, the authors compared the transplant outcomes of patients who developed graft failure and underwent salvage transplantation from haploidentical donor and cord blood from 2007 to 2016. [Bone Marrow Transplant] Abstract Scientists characterized the differentiation of Wharton’s jelly derived MSCs using neuronal conditioned medium collected from cultured fetal brain cells. [Int J Neurosci] Abstract Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News. | |
| |
REVIEWSWharton’s Jelly MSCs: Potential Weapon to Sharpen for Our Battle against DM The authors discuss major advantages of Wharton’s jelly-MSCs and challenges facing their clinical utility in diabetes mellitus (DM). [Trends Endocrinol Metab] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSMesoblast Submits Completed Biologics License Application for Ryoncil™ to US FDA Mesoblast Limited announced that it has submitted its completed Biologics License Application to the FDA for Ryoncil™, its lead allogeneic cell therapy for the treatment of children with steroid-refractory acute graft versus host disease. [Mesoblast Limited] Press Release Kite announced that the FDA has accepted the BLA and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. [Gilead Sciences, Inc.] Press Release | |
| |
POLICY NEWSPopular Preprint Servers Face Closure Because of Money Troubles The rise of preprint repositories has helped scientists worldwide to share results and get feedback quickly. But several platforms that serve researchers in emerging economies are struggling to raise money to stay afloat. Repositories like INA-Rxiv and IndiaRxiv boost regional science, but finding cash to run them is proving difficult. [Nature News] Editorial FDA Now Allows Certain Lab Animals to Be Retired and Adopted The US Food and Drug Administration will now permit certain animals used in experiments to retire and be adopted rather than face euthanasia, according to internal documents reviewed by The Hill. Although the policy changed in November, there have not been any public statements from the agency. [The Scientist] Editorial
| |
EVENTSNEW 2020 American Association of Blood Banks (AABB) Annual Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Laboratory Director – Cord Blood Processing (PerkinElmer) Scientist – Hematopoietic Stem and Progenitor Cell Biology (STEMCELL Technologies Inc.) Research Associate – Cell Culture (Rogosin Institute) Postdoctoral Research Fellow – Regenerative Medicine (University of Edinburgh) Postdoctoral Fellow – Cancer Immunotherapy/CAR T Cell Development (City of Hope) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|